Nachrichten zur NAVAMEDIC ASA NK 1 Aktie

Observe Medical ASA: Amendments to loan agreements with Navamedic ASA

Oslo, 15 November 2024: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on…

Navamedic ASA: Mandatory notice of trade

Oslo, November 6, 2024: Lars Hjarrand, CFO and a primary insider of Navamedic ASA, has today bought 20.000 Navamedic ASA…

Navamedic launches Eroxon[®] in Finland

Oslo, 6 November 2024 – Building on the successful product launch of Eroxon[®] in Norway and Sweden earlier this year,…

NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS

Oslo, 9 September 2024: The board of directors of Navamedic ASA (the "Company"), has today, on 9 September 2024, in…

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

Oslo, 16 August 2024 – In first half of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable…

Navamedic ASA: Notice of Annual General Meeting

The annual general meeting of Navamedic ASA (OSE: NAVA) will be held on Tuesday, June 4th 2024 at 09:00 (CET)…

Navamedic ASA: Annual Report 2023

Oslo, 30 April 30 2024 -  Navamedic ASA has today published its Annual Report for 2023 approved by the Board…

Navamedic Q1 2024: Successful product launch and steady operational progress

Oslo, 30 April 2024 – In the first quarter 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable…

Navamedic ASA: Resolution to increase the share capital in connection with exercise of employee options

Oslo, 15 March 2024: The board of directors of Navamedic ASA (the "Company"), has today, on 15 March 2024, in…

Navamedic ASA: Notification of major shareholding and mandatory notification of trade

Oslo, 12 March 2024 - Ingerø Reiten Investment Company AS ("IRIC") has today sold all of its shares in the…

Navamedic ASA: Mandatory notification of trade

Åsa Kornfeld and Edmée Steenken, both primary insiders and Board members in Navamedic ASA, have on 22 February 2024 purchased…

Navamedic ASA launches Eroxon®

Oslo, 12 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals…

Navamedic ASA: Renewed contract signed with Vitaflo International Limited

Oslo, 21 December 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to…

Disclosure of large shareholding

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the allocation of shares…

Navamedic ASA: Record high quarter with above 50 percent growth

Oslo, 1 November 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to…

RLS Global appoints Torbjörn Sannerstedt as new Chief Financial Officer

RLS Global AB (publ) today announces that Torbjörn Sannerstedt has been appointed new Chief Financial Officer (CFO). Torbjörn succeeds RLS…

Navamedic ASA - Mandatory notification of trade by primary insider

OSLO, Norway, Aug. 18, 2023 /PRNewswire/ -- Reference is made to the stock exchange announcement published earlier today, on 18…

Navamedic ASA – Mandatory notification of trade by primary insider

Oslo, 18 August 2023: Reference is made to the stock exchange announcement published earlier today, on 18 August 2023 by…

NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options

Oslo, 18 August 2023: The board of directors of Navamedic ASA (the "Company"), has today, on 18 August 2023, in…

Navamedic ASA: Significant growth across the business

OSLO, Norway, Aug. 11, 2023 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality…

Navamedic ASA: Significant growth across the business

Oslo, 11 August 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to…

Navamedic ASA: Invitation to 2023 2nd quarter presentation

OSLO, Norway, Aug. 7, 2023 /PRNewswire/ -- Navamedic ASA (OSE: Nava) will be presenting its second quarter 2023 results and…

Navamedic ASA: Invitation to 2023 2nd quarter presentation

Oslo, August 7, 2023 - Navamedic ASA (OSE: Nava) will be presenting its second quarter 2023 results and publish its…

Navamedic ASA: Minutes of Annual General Meeting

OSLO, Norway, June 1, 2023 /PRNewswire/ -- The Annual General Meeting of Navamedic ASA was held today at 10:00 CEST.…

Navamedic ASA: Minutes of Annual General Meeting

Oslo, 1 June 2023: The Annual General Meeting of Navamedic ASA was held today at 10:00 CEST. All items on…

Updated recommendation by the nomination committee of Navamedic ASA

Following Navamedic ASAs acquisition of Sensidose AB, the nomination committee recommends that Åsa Kornfeld, previous Board member in Sensidose AB,…

Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

OSLO, Norway, May 26, 2023 /PRNewswire/ -- Following the closing of the acceptance period in the previously announced public offer,…

Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

Oslo, 26 May 2023 – Following the closing of the acceptance period in the previously announced public offer, Navamedic ASA…

Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South…

Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South…

Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South…

Navamedic ASA: Notice of Annual General Meeting

OSLO, Norway, May 11, 2023 /PRNewswire/ -- The annual general meeting of Navamedic ASA (OSE: NAVA) will be held on…

Navamedic ASA: Notice of Annual General Meeting

The annual general meeting of Navamedic ASA (OSE: NAVA) will be held on Thursday, June 1st 2023 at 10:00 (CET)…

Navamedic ASA Q1 2023: Another strong quarter

OSLO, Norway, May 11, 2023 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality…

Navamedic ASA Q1 2023: Another strong quarter

Oslo, 11 May 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to…

Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag

OSLO, Norway, May 10, 2023 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and provider of high-quality products…

Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South…

Navamedic ASA: Invitation to 2023 1st quarter presentation

OSLO, Norway., May 8, 2023 /PRNewswire/ -- Navamedic ASA (OSE: Nava) will be presenting its first quarter 2023 results on…

Navamedic ASA: Invitation to 2023 1st quarter presentation

Oslo, May 8, 2023 - Navamedic ASA (OSE: Nava) will be presenting its first quarter 2023 results on Thursday May…

Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South…

Navamedic ASA: Annual Report for 2022

OSLO, Norway, April 28, 2023 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality…

Navamedic ASA: Annual Report for 2022

Oslo, 28 April 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to…

Navamedic increases the consideration to SEK 0.60 in cash per warrant of series TO 1 in its unconditional offer to the warrant holders in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South…

Navamedic ASA expands its offer to include warrants of series TO 1 issued by Sensidose Aktiebolag at a price of SEK 0.38 in cash per warrant of series TO 1

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South…

Correction: Navamedic publishes a supplement to the offer document regarding the cash offer to the shareholders of Sensidose Aktiebolag

Press release 24 April 2023 Navamedic ASA published a press release on 24 April 2023 21:30 p.m. (CEST). The following is a…

Navamedic publishes a supplement to the offer document regarding the recommended cash offer to the shareholders of Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South…

Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

OSLO, Norway, April 24, 2023 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and provider of high-quality products…

Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

Oslo, 22 April 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and provider of high-quality products to hospitals…

Navamedic completes the offer, has entered into agreements to acquire approximately 56.7 per cent of the shares in Sensidose and increases the consideration to SEK 8 in cash per share

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South…

Navamedic announces $7.2m cash offer for Sensidose acquisition

The independent bid committee of Sensidose has recommended the cash offer. At present, the shares of Sensidose are listed on…